Abstract:Abstract Background Anti-nerve growth factor (NGF) monoclonal antibodies (anti-NGF mAbs) have been reported to significantly attenuate pain, but the mechanism involved has not been fully elucidated, and the serious adverse events associated with mAbs seriously limit their clinical use. This study further investigated the mechanism by which peripheral NGF is involved in neuropathic pain and found safe, natural compounds that target NGF to attenuate neuropathic pain. Methods Nociception was assessed by the Von Frey hair and Hargreaves’ methods. Western-blotting, qPCR and immunofluorescence were used to detect the cell signaling pathway. RAW264.7 macrophages and RSC96 Schwann cells were cultured for in vitro evaluation. Results Intraplantar administration of anti-NGF mAbs suppressed the expression of phosphorylated transforming growth factor-β-activated kinase 1 (TAK1) in the dorsal root ganglion (DRG) and sciatic nerve. Intraplantar administration of a TAK1 inhibitor attenuated CCI-induced neuropathic pain and suppressed the expression of phosphorylated mitogen-activated protein kinases (MAPKs) in the DRG and sciatic nerve. Perisciatic nerve administration of levo- corydalmine ( l- CDL) on the operated side obviously attenuated CCI-induced neuropathic pain and suppressed the expression of mNGF and proNGF. In addition, l -CDL-induced antinociception was reversed by intraplantar administration of NGF. Further results indicated that l- CDL-induced suppression of phosphorylated TAK1, MAPKs, and p65 and expression of the proinflammatory cytokines TNF-α and IL-1β in the DRG and sciatic nerve were all abolished by NGF. In addition, in vitro experiments indicated that l- CDL suppressed the secretion of NGF and proNGF in RAW264.7 macrophages and RSC96 Schwann cells, which was abolished by AP-1 and CREB agonists, respectively. Conclusions This study showed NGF inhibition suppressed TAK1 in the periphery to attenuate CCI-induced neuropathic pain through inhibition of downstream MAPK and p65 signaling. The natural compound l- CDL inhibited NGF secretion by macrophages and Schwann cells and downstream TAK1-MAPK/NF-κB signaling in the periphery to attenuate CCI-induced neuropathic pain. Graphical abstract Proposed mechanisms underlying the effect of l -CDL in periphery of CCI rats. In CCI rats, macropahages and Schwann cells could secret NGF to act on the receptors in the periphery to activate TAK1-MAPK/NF-κB axis and promote the release of proinflammatory cytokines, including TNF-α and IL-1β to promote neuropathic pain. l -CDL decreased the secretion of NGF through inhibiting AP-1 and CREB respectively in RAW264.7 and RSC96 Schwann cells to attenuate CCI-induced neuropathic pain by inhibiting the TAK1-p38 MAPK/NF-κB signaling pathway.

Cynandione A attenuates neuropathic pain through p 38 β MAPK-mediated spinal 1 microglial expression of β-endorphin 2 3

Cynandione A Attenuates Neuropathic Pain Through P38β MAPK-mediated Spinal Microglial Expression of Β-Endorphin

Cynandione A alleviates neuropathic pain through spinal microglial interleukin-10/β-endorphin expression following α7 nicotinic acetylcholine receptor activation

Cynandione A Alleviates Neuropathic Pain Through α7-nAChR-Dependent IL-10/β-Endorphin Signaling Complexes

Cynandione A Mitigates Ischemic Injuries in Rats with Cerebral Ischemia

The Analgesia Effect of Aucubin on CFA-Induced Inflammatory Pain by Inhibiting Glial Cells Activation-Mediated Inflammatory Response via Activating Mitophagy

Down-regulation of NR2B receptors partially contributes to analgesic effects of Gentiopicroside in persistent inflammatory pain.

Cynandione A and PHA-543613 inhibit inflammation and stimulate macrophageal IL-10 expression following α7 nAChR activation

The analgesic effect and mechanism of the active components screening from Corydalis yanhusuo by P2X3 receptors

The Aqueous Extract of Armadillidium vulgare Latreille Alleviates Neuropathic Pain via Inhibiting Neuron-Astrocyte Crosstalk Mediated by the IL-12-IFN-γ-IFNGR-CXCL10 Pathway

Influence of Intrathecal Injection of P38 MAPK Inhibitor on BDNF Expression in Dorsal Horn of Spinal Cord of Rats with Neuropathic Pain

Andrographolide Inhibits the Activation of Spinal Microglia and Ameliorates Mechanical Allodynia.

Activation of GPR40 Produces Mechanical Antiallodynia Via the Spinal Glial Interleukin-10/Β-endorphin Pathway

Protopanaxadiol Alleviates Neuropathic Pain by Spinal Microglial Dynorphin A Expression Following Glucocorticoid Receptor Activation.

Curcumin Attenuates Microglia-Mediated Chronic Neuropathic Pain Through CDK5 /p35 Signaling Pathway

Anxiolytic effects of polydatin through the blockade of neuroinflammation in a chronic pain mouse model

Effects of intermedin on dorsal root ganglia in the transmission of neuropathic pain in chronic constriction injury rats.

Tibetan medicine Ruyi Zhenbao Pill ameliorates neuropathic pain by inhibiting the CXCL10-CXCR3 pathway in spinal cord of spinal nerve ligation model

The Analgesic Effects of Β-Elemene in Rats with Neuropathic Pain by Inhibition of Spinal Astrocytic ERK Activation.

Activation of G protein-coupled receptor 39 alleviates neuropathic pain and chronic inflammation

Suppression of peripheral NGF attenuates neuropathic pain induced by chronic constriction injury through the TAK1-MAPK/NF-κB signaling pathways